Patents Assigned to Merck Sharp & Dohme Corp.
  • Publication number: 20210317214
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and the use of the combination therapies for the treatment of non-microsatellite instability-high (non-MSI-H) or proficient mismatch repair (pMMR) colorectal cancer.
    Type: Application
    Filed: September 9, 2019
    Publication date: October 14, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Elliot K. Chartash, Terrill K. McClanahan, Jane Anne Healy
  • Publication number: 20210317091
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an 1DO-associated disease or disorder.
    Type: Application
    Filed: November 9, 2018
    Publication date: October 14, 2021
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Yongxin Han, Abdelghani Achab, Indu Bharathan, Xavier Fradera, Derun Li, Nunzio Sciammetta, Wensheng Yu
  • Publication number: 20210317215
    Abstract: The invention provides methods for producing crystalline an anti-PD-1 monoclonal antibody (mAb), wherein the mAb is pembrolizumab or a pembrolizumab variant, comprising (1) mixing a solution comprising (a) the mAb, (b) polyethylene glycol (PEG), and (c) an additive selected from the group consisting of: caffeine, theophylline, 2? deoxyguanosine-5?-monophosphate, a bioactive gibberellin, and a pharmaceutically acceptable salt of said bioactive gibberellin, to form a crystallization solution, (2) incubating the crystallization solution for a period of time sufficient for crystal formation; and (3) optionally harvesting the crystalline anti-PD-1 mAb from the solution. In specific embodiments, the PEG is PEG 3350 and the additive is caffeine. The invention also relates to the novel anti-human PD-1 mAb crystals produced by the methods described herein.
    Type: Application
    Filed: October 28, 2019
    Publication date: October 14, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Paul Reichert, Winifred W. Prosise, Xiaoyu Yang, Corey Strickland, Chakravarthy Nachu Narasimhan, Thierry O. Fischmann, Erika R. Walsh, Yongchao Su
  • Publication number: 20210317441
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Application
    Filed: June 10, 2021
    Publication date: October 14, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • Patent number: 11141410
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: October 12, 2021
    Assignee: MERCK SHARP & DOHME CORP
    Inventors: John P. Caldwell, Reynalda De Jesus, Fa-Xiang Ding, Charles J. Gill, Ginny Dai Ho, Sookhee N. Ha, Sandra J. Koseoglu, Marc A. Labroli, Sang Ho Lee, Christina Madsen-Duggan, Mihir Mandal, Terry Roemer, Jing Su, Christopher Michael Tan, Zheng Tan, Haifeng Tang, Hao Wang, Christine Yang, Shu-Wei Yang
  • Patent number: 11141403
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: October 12, 2021
    Assignee: MERCK SHARP & DOHME CORP
    Inventors: John P. Caldwell, Ginny Dai Ho, Sookhee N. Ha, Sandra J. Koseoglu, Marc A. Labroli, Sang Ho Lee, Christina Madsen-Duggan, Mihir Mandal, Jianping Pan, Weidong Pan, Terry Roemer, Jing Su, Christopher Michael Tan, Zheng Tan, Hao Wang, Christine Yang, Shu-Wei Yang
  • Patent number: 11141539
    Abstract: An injector for delivering liquid can include a body having a proximal end, a distal end, a longitudinal axis, and a track follower adjacent to the proximal end. A plunger can be disposed at least partially within the body and movable with respect to the body along the longitudinal axis. An actuator can be positioned at the proximal end of the body and operably connected to the plunger. The actuator can include a track having a first portion and a second portion. The first portion can limit travel of the actuator along the longitudinal axis to deliver a first predetermined amount of the liquid. The second portion can limit travel of the actuator along the longitudinal axis to deliver a second predetermined amount of the liquid. The actuator can be positionable to selectively control displacement of the plunger pursuant to the first portion or the second portion of the track.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: October 12, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jeffrey C. Givand, Peter A. Basile
  • Publication number: 20210309671
    Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, where-in R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: May 31, 2019
    Publication date: October 7, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Tao YU, Alan WHITEHEAD, Yili CHEN, Chunrui SUN, Zhiyong HU, Kake ZHAO, Ronald M. KIM, John A. McCAULEY
  • Publication number: 20210309687
    Abstract: The present invention provides a compound of formula (I) Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, are PRMT5 inhibitors. Also provided are methods of making compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I), and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
    Type: Application
    Filed: August 5, 2019
    Publication date: October 7, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michelle Machacek, David Witter, Chunhui Huang, Shuhei Kawamura, Sebastian Schneider, Murray Wan
  • Publication number: 20210309688
    Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
    Type: Application
    Filed: August 5, 2019
    Publication date: October 7, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Michelle Machacek, Michael H. Reutershan, Sebastian Schneider
  • Publication number: 20210309650
    Abstract: The present invention is directed to processes for preparing a diazepane compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is further directed to crystalline forms of this diazepane compound and pharmaceutical compositions thereof.
    Type: Application
    Filed: July 16, 2015
    Publication date: October 7, 2021
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Ltd.
    Inventors: Carl A. Baxter, Edward Cleator, Faye Sheen, Shane W. Krska, Gavin Stewart, Neil Strotman, Debra J. Wallace, Timothy Wright
  • Publication number: 20210299247
    Abstract: The present invention relates to stable formulations of a cytomegalovirus (CMV) comprising for example, a genetically modified CMV that is conditionally replication defective, a buffer, alkali or alkaline salt, a sugar, a cellulose derivative and optionally a polyol.
    Type: Application
    Filed: October 29, 2018
    Publication date: September 30, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Muneeswara Babu Medi, Harrison Bradford Davis, Lorenzo H. Chen, Lynne Ann Isopi, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler
  • Patent number: 11130802
    Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: September 28, 2021
    Assignees: Tilos Therapeutics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Randall Burton, Jessie M. English, Barbara S. Fox, Stavros Kopsiaftis, Renee Moore, Patricia Rao, Kenneth J. Simon
  • Publication number: 20210290548
    Abstract: The present invention is directed to compressed tablets for oral administration, which comprise an intragranular component comprising the potassium salt of raltegravir, an inert superdisintegrant, and a binder; and an extragranular component comprising a superdisintegrant and a lubricant.
    Type: Application
    Filed: May 31, 2019
    Publication date: September 23, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Majid Mahjour, Ronald L. Smith
  • Publication number: 20210293818
    Abstract: The instant invention describes a virus reduction neutralization test (VRNT) which is a rapid, high throughput alternative to current standard low throughput and laborious neutralization assays. The VRNT utilizes imaging cytometry to count virus-infected cells at about one day post-infection (thus eliminating the wait time other assays employ allowing for viral infection cell to cell), reducing overall assay time and increasing throughput at least 15-fold.
    Type: Application
    Filed: August 9, 2019
    Publication date: September 23, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Melissa C. Whiteman, Joseph M. Antonello, Leah A. Bogardus, Danila G. Giacone, Dengyun Sun, Amy H.M. Tou, Kevin B. Gurney, Leonard J. Rubinstein
  • Patent number: 11123499
    Abstract: The present invention relates to drug delivery systems that cannot be reloaded or reused and further include a passive safety shield system. The drug delivery devices described herein include a drug container comprising at least one bellow, a needle, wherein the needle is in liquid communication with the drug container; a plunger extending between a proximal end and a distal end, wherein the plunger is in communication with the drug container and where upon axial movement of the plunger, the drug container is compressed.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: September 21, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter A. Basile, Steven Carl Persak, Mikhail Gotliboym, Brad Britland, Stephen G. Miggels, Henry J. Mack, Jr., Oliver J. Sha
  • Patent number: 11123355
    Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 21, 2021
    Assignees: Idenix Pharmaceuticals LLC, Merck Sharp & Dohme Corp.
    Inventors: Manuel de Lera Ruiz, Timothy J. Hartingh, Izzat Raheem, John Schreier, Jean-Laurent Paparin
  • Patent number: 11124478
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: September 21, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Publication number: 20210283161
    Abstract: The instant invention relates to a method for reducing the risk for development of anti-viral treatment resistance due to an HIV mutation in a human subject infected with HIV, comprising administering EFdA in combination with one or more anti-viral agents.
    Type: Application
    Filed: July 12, 2019
    Publication date: September 16, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Daria Jean Hazuda, Ming-Tain Lai
  • Patent number: 11116828
    Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: September 14, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: William J. Smith, Patrick McHugh, Michael Albert Winters, Julie M. Skinner, Jian He, Luwy Musey, Chitrananda Abeygunawardana, Yadong Adam Cui, Michael J. Kosinski